JP2025508798A - 脂質とブロックコポリマーとを含むポリマー-脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法 - Google Patents

脂質とブロックコポリマーとを含むポリマー-脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法 Download PDF

Info

Publication number
JP2025508798A
JP2025508798A JP2024549607A JP2024549607A JP2025508798A JP 2025508798 A JP2025508798 A JP 2025508798A JP 2024549607 A JP2024549607 A JP 2024549607A JP 2024549607 A JP2024549607 A JP 2024549607A JP 2025508798 A JP2025508798 A JP 2025508798A
Authority
JP
Japan
Prior art keywords
polymer
peo
lipid
lipid hybrid
pbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508798A5 (cg-RX-API-DMAC10.html
Inventor
マドハバン ナラーニ
テック ワン キア
シャオチョン リウ
ガウラヴ シンシンバー
ジェン ハン ラム
Original Assignee
エイシーエム バイオラブズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシーエム バイオラブズ プライベート リミテッド filed Critical エイシーエム バイオラブズ プライベート リミテッド
Publication of JP2025508798A publication Critical patent/JP2025508798A/ja
Publication of JP2025508798A5 publication Critical patent/JP2025508798A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024549607A 2022-02-23 2023-02-23 脂質とブロックコポリマーとを含むポリマー-脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法 Pending JP2025508798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158324.8 2022-02-23
EP22158324 2022-02-23
PCT/EP2023/054613 WO2023161378A1 (en) 2022-02-23 2023-02-23 Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof

Publications (2)

Publication Number Publication Date
JP2025508798A true JP2025508798A (ja) 2025-04-10
JP2025508798A5 JP2025508798A5 (cg-RX-API-DMAC10.html) 2026-03-02

Family

ID=80448440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549607A Pending JP2025508798A (ja) 2022-02-23 2023-02-23 脂質とブロックコポリマーとを含むポリマー-脂質ハイブリッドナノ粒子ならびにその作製方法および使用方法

Country Status (6)

Country Link
US (1) US20250235532A1 (cg-RX-API-DMAC10.html)
EP (1) EP4482477A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508798A (cg-RX-API-DMAC10.html)
AU (1) AU2023226175A1 (cg-RX-API-DMAC10.html)
CA (1) CA3244864A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023161378A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026062291A1 (en) 2024-09-23 2026-03-26 Aldexchem Kft. Silicon-containing spleen-targeted lnp delivery systems
WO2026129142A1 (zh) * 2024-12-17 2026-06-25 西湖实验室(生命科学和生物医学浙江省实验室) 新型脂质纳米颗粒系统、car-t构建方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
CA3170184A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CN111450060A (zh) 2012-11-19 2020-07-28 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
US20150366997A1 (en) * 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
JP2017520549A (ja) * 2014-06-26 2017-07-27 ラモット アット テル アビブ ユニバーシティ, リミテッド 核酸の送達のためのリポソーム製剤
WO2016154432A1 (en) 2015-03-24 2016-09-29 VaxLiant, LLC Adjuvant compositions and related methods
CN116322788A (zh) * 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法

Also Published As

Publication number Publication date
EP4482477A1 (en) 2025-01-01
WO2023161378A1 (en) 2023-08-31
CA3244864A1 (en) 2023-08-31
AU2023226175A1 (en) 2024-10-03
US20250235532A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
JP7676030B2 (ja) 関連づけられた抗原を有するポリマーソームの集団を、関連づけられたアジュバントを有するポリマーソームの集団と一緒に投与することによって、免疫応答を誘発する方法、およびそれら2つのポリマーソーム集団を含む組成物
Hao et al. Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
US10920246B2 (en) Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
JP2021175750A (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
ES2907486T3 (es) Métodos y composiciones para reducir metástasis
JP5835741B2 (ja) 抗原または薬物送達複合体
JP2023526422A (ja) コロナウイルス抗原組成物及びそれらの使用
ES2924138T3 (es) Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
CN116744979A (zh) 包含甘露糖的脂质纳米颗粒或其应用
CN118159278A (zh) 单链可变片段(scFv)修饰的脂质纳米颗粒组合物及其用途
US20250235532A1 (en) Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof
CN116744940A (zh) 用于治疗癌症的治疗性rna
CA3246723A1 (en) Lipid nanoparticle compositions for the delivery of plasma DNA to the liver and their preparation methods
AU2022258552A1 (en) Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
WO2015095866A1 (en) Methods and compositions for enhanced cellular selectivity using nanocarrier-associated ligands
US20230398207A1 (en) Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CA3205397A1 (en) Composition for preventing or treating cancer, containing lipid nanoparticles
KR20220149400A (ko) 이황화 결합을 갖는 양이온성 지질을 사용하여 약물을 전달하기 위한 나노입자 조성물 및 그 제조방법
JP2025529906A (ja) コロナウイルスに対するワクチン
EP4288033B1 (en) Polymersome associated adjuvant for use in stimulating an immune response
JP5817053B2 (ja) 腫瘍特異性を有するリポソーム
WO2022097634A1 (ja) 血管新生依存性疾患治療に使用される医薬用組成物
Qelliny et al. Immune Responses to PEGylated lipoplexes, a review
WO2024092352A1 (en) Compositions that recruit and activate antigen presenting cells
WO2025249511A1 (ja) メッセンジャーrnaを腫瘍組織に導入するために用いられる組成物およびがん治療用医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260219

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260630

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260722